Tecentriq (atezolizumab) / Roche - LARVOL DELTA

IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. (PubMed, Future Oncol) - P3 | "The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. IMvigor011 (NCT04660344) is a global, double-blind, randomized phase III study assessing the efficacy of atezolizumab (anti-PD-L1) versus placebo in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive post-cystectomy. The primary end point is disease-free survival in participants who are ctDNA positive within 20 weeks of cystectomy."

Circulating tumor DNA • Journal • Post-surgery • Review • Surgery • Bladder Cancer • Genito-urinary Cancer • Immune Modulation • Oncology • Solid Tumor • Urothelial Cancer

Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial. (ASCO-GU 2026) - P3 | "For most pts identified as ctDNA+ via serial ctDNA monitoring after RC, positivity was evident ≤24 wk. Early positivity and high baseline concentrations were negative prognostic factors. Atezo treatment prevented the rapid increase in ctDNA levels observed in the pbo arm and led to enhanced ctDNA clearance, which was associated with superior clinical outcomes."

Circulating tumor DNA • Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer (IASLC-WCLC 2026) - P1/2 | "Conclusions : Consolidation atezolizumab in ASTRES demonstrated an efficacy profile consistent with the expected outcomes of anti-PD-L1 therapy in unresectable, stage III, NSCLC. Single-agent atezolizumab demonstrated a safety profile consistent with its well-established monotherapy safety profile and no new safety signals were identified."

Metastases • P2 data • Hepatology • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatitis • Pneumonia • Respiratory Diseases • Solid Tumor

Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data (IASLC-WCLC 2026) - P2 | "Post-resection, patients with programmed death-ligand 1 tumor cell (PD-L1 TC) <1% received either adjuvant chemotherapy followed by up to 3 years of divarasib, up to 3 years of divarasib monotherapy, or standard of care; patients with PD-L1 TC ≥1% received adjuvant chemotherapy followed by atezolizumab, or standard of care. Divarasib also demonstrated manageable safety in the adjuvant setting. Divarasib will be investigated further in early-stage, resectable NSCLC in the phase III Krascendo 3 trial."

Clinical • IO biomarker • Constipation • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • KEAP1 • KRAS • PD-L1 • STK11 • TP53

Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC (IASLC-WCLC 2026) - P3 | "The control arm performed better than historic controls. No new safety signals were identified."

P3 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR

First-Line Maintenance With Serplulimab for Extensive-Stage Small Cell Lung Cancer: A Post-Hoc Analysis and Meta-Analysis (IASLC-WCLC 2026) - "As shown in Table 1, compared with atezolizumab, serplulimab was associated with more favorable OS (hazard ratio [HR], 0.63; 95% CI, 0.48-0.81) and PFS (HR, 0.62; 95% CI, 0.49-0.80); compared with atezolizumab plus lurbinectedin, serplulimab was associated with improved OS (HR, 0.74; 95% CI, 0.57-0.97), similar PFS (HR, 1.01; 95% CI, 0.77-1.31), and an approximately 50% lower risk of grade ≥3 TRAEs (risk ratio, 0.52; 95% CI, 0.38-0.72). Conclusions : In this inter-study comparison, serplulimab was associated with more favorable OS and PFS than atezolizumab and with more favorable OS and safety than atezolizumab plus lurbinectedin."

Retrospective data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer (IASLC-WCLC 2026) - P3 | "Methods : The expression and prognostic impact of B7-H3 was analyzed using tumor samples from patients with ES-SCLC enrolled in the IMpower133 (NCT02763579), and SKYSCRAPER-02 (NCT04256421) studies and who received either carboplatin/etoposide (CE) or atezolizumab plus CE (ACE). B7-H3 expression is not strongly correlated with SCLC transcription factors or canonical surface antigens, suggesting broad expression across disease subsets. B7-H3 expression is also not a prognostic factor for PFS or OS in patients from the IMpower133 and SKYSCRAPER-02 studies."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276 • PD-L1

ATHENEA, a Phase II Study of Atezolizumab as Neoadjuvant, Adjuvant and Maintenance Treatment for Stage IIIA-IIIB NSCLC Patients (IASLC-WCLC 2026) - "The standard treatment for unresectable stage III patients is concurrent chemoradiotherapy (cCRT) followed by durvalumab for 1 year (PACIFIC regimen)...Methods : ATHENEA is an ongoing multicenter, open-label, phase II clinical trial (EUCT Number: 2024-515984-68-00) that evaluates the efficacy of 3 cycles of neoadjuvant treatment with atezolizumab 1200 mg plus carboplatin AUC6 and paclitaxel 200mg/m 2 in stage IIIA and IIIB NSCLC patients...Patients will undergo tumor assessments by body CT scan at baseline, at post neoadjuvant treatment prior to surgery or cCRT, after surgery (for resectable patients), after cCRT treatment (for non-resectable patients), during treatment with atezolizumab in adjuvant/post cCRT phase every 12 weeks and thereafter, every 3 months for the first 2 years and every 6 months until the 5-year follow-up period is completed. Currently 47 patients have been included in the study."

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR • ROS1 • STK11

Randomized trial of serplulimab or atezolizumab plus chemotherapy in USA patients with extensive-stage small cell lung cancer (ASTRIDE) (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "In patients with advanced hepatocellular carcinoma with macrovascular invasion after systemic therapy, time to treatment failure was longer in those who had liver resection than in those who received maintenance therapy."

Clinical • Journal • P3 data • Hepatocellular Cancer • Hepatology • Liver Failure • Oncology • Renal Disease • Solid Tumor

The Road Less Traveled: Esophageal Metastasis of Hepatocellular Carcinoma (ACG 2026) - "Avastin and atezolizumab were discontinued due to disease progression (rising AFP)...Ipilimumab and nivolumab were discontinued after hospitalization due to another GIB event. Brigatinib was well tolerated...Figure: Figure 1. One 15 mm polyp was found 27 cm from the incisors on EGD obtained for indications of dysphagia and esophageal variceal surveillance."

Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus • AFP

Immune-Related Adverse Events and Infections in Cancer Patients With Splenectomy Receiving Immune Checkpoint Inhibitor Therapy (ACG 2026) - "59.8 % of irAE patients required systemic steroids, with 17.1% needing high-dose therapy (â¥1mg/kg prednisone equivalent)...cImmunosuppressants: bevacizumab, rituximab, imatinib, lenalidomide, 5-azacitinide dICI agents by class: Anti-PD-1: pembrolizumab, nivolumab, cemiplimab, tislelizumab, toripalimab, zimberelimab. Total 293 patients met the inclusion criteria. Primary malignancies: 31.7 % GI, 18.8% GU, and 11.3% lung. Asplenic patients had lower irAE severity compared to general populations: high-grade irAEs (⥠3) occurred in 10.6% of all patients versus 19.7% in general ICI-treated populations, despite 20.5% of patients receiving combination ICI therapy."

Adverse events • Checkpoint inhibition • Clinical • Hematological Malignancies • Infectious Disease • Nephrology • Oncology • Pneumonia • Respiratory Diseases

Metastatic Small Cell Lung Cancer to the Uncinate Process of the Pancreas: A Rare Presentation Complicated by Biliary Obstruction and Failed ERCP (ACG 2026) - "He was treated with carboplatin, etoposide, and atezolizumab, followed by surgical resection of the primary lung mass and stereotactic radiosurgery, achieving remission until 2023...DLL3 positivity further guided third-line therapy with tarlatamab...Findings suggest local invasion into the duodenal muscularis propria. Fine needle biopsy was performed."

Metastases • Hepatology • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Small Cell Lung Cancer • Solid Tumor • DLL3 • NKX2-1 • SYP

EUS Guided Gastro-Jejunostomy for Management of Gastric Outlet Obstruction Secondary to Y90 Induced Ulceration (ACG 2026) - "She underwent 4 Y90 treatments and subsequently began atezolizumab plus bevacizumab...She was treated with a proton pump inhibitor and sucralfate...By restoring luminal patency, this approach can meaningfully improve oral intake and nutritional status during ulcer healing. Figure: Esophagoduodenoscopic images of the gastric antrum demonstrating an ulcer and obstruction Figure: Esophagoduodenoscopic images of the gastric antrum demonstrating an AXIOS LAMS deployment and a clip deployed to close the site of inadvertent stent misplacement"

Fibrosis • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Immunology • Peptic Ulcer • Solid Tumor

Exceptional Pathologic Response to Multimodal Therapy in Massive Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombus Leading to Curative Liver Transplantation (ACG 2026) - "Atezolizumab plus Bevacizumab was initiated but discontinued due to hyperbilirubinemia; the patient was subsequently switched to Durvalumab monotherapy. B. Medium power view (x100 magnification) with rare, scattered microscopic foci of residual hepatocellular carcinoma surrounded by necrosis and treatment-related changes"

Clinical • IO biomarker • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor • Thrombosis • Transplantation • AFP

Immunotherapy in a Pre-Transplant Patient With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Promising Tertiary Center Experience (ACG 2026) - "Atezolizumab and bevacizumab (Atezo/Bev), a first line immunotherapy for primary HCC, has been proposed as a treatment for patients with cHCC-CCA. (E-F) CCA component characterized by malignant glandular structures. All microphotographs are from H&E -stained slides."

Clinical • Pre-transplantation • Biliary Cancer • Cholangiocarcinoma • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Oncology • Solid Tumor • Thrombosis • Transplantation • AFP

Comparing Efficacy and Toxicity of STRIDE Versus Atezolizumab-Bevacizumab in Hepatocellular Carcinoma (ACG 2026) - "Introduction: Single tremelimumab regular interval durvalumab (STRIDE) and atezolizumab-bevacizumab (atezo-bev) are preferred systemic therapies for hepatocellular carcinoma (HCC). Of 242 patients, 99 (41%) received STRIDE. STRIDE was associated with lower disease control rate compared to atezo-bev (47.5% vs 66.4%, RR 0.71, 95% CI 0.56-0.91, p=0.003). On IPTW-Cox regression, OS (HR 0.73, 95% CI 0.50-1.07, p=0.111), real-world PFS (HR 0.82, 95% CI 0.58-1.15, p=0.248), and time on treatment (HR 0.86, 95% CI 0.62-1.19, p=0.366) were similar comparing STRIDE vs atezo-bev."

Clinical • Cardiovascular • Hepatocellular Cancer • Oncology • Solid Tumor

Malignant Mimics of Esophageal Motility Disorders: Two Cases of Pseudoachalasia and One Case of Secondary EGJOO (ACG 2026) - "Case Description/ A 65-year-old male with stage IV small cell lung cancer developed rapid onset dysphagia after starting atezolizumab...Fine needle biopsies confirmed malignant mesothelioma. Pseudoachalasia and secondary EGJOO are rare and require a high index of clinical suspicion, particularly given their association with malignancy and the prognostic implications of delayed diagnosis."

Clinical • Gastrointestinal Disorder • Lung Cancer • Mesothelioma • Rare Diseases • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor

Rapidly Progressive Combined Hepatocellular-Cholangiocarcinoma in a Non-Cirrhotic, Seronegative Patient (ACG 2026) - "Atezolizumab-bevacizumab was recommended. Treatment delays in oncology carry measurable consequences. The gap between diagnosis and"

Clinical • IO biomarker • Biliary Cancer • Cholangiocarcinoma • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Immune Checkpoint Inhibitor-Associated Colitis and Subsequent Colonic Adenoma Risk: Evidence From a Federated Health Record Database (ACG 2026) - "Adult patients (18 years and older) who received ICIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, avelumab, or cemiplimab) were included. After matching, the baseline characteristics were similar across both groups. Patients with ICI-related colitis faced higher risks for colonic adenoma (4.9% vs 2.7%; RR 1.78, p < 0.001), colectomy (0.33% vs 0.15%; RR 2.13, p = 0.002), gastrointestinal bleeding (13.0% vs 7.4%; RR 1.75, p < 0.001), intestinal perforation (1.6% vs 0.7%; RR 2.49, p < 0.001), and sepsis (21.0% vs 15.9%; RR 1.32, p < 0.001). The incidence of colorectal cancer was not significantly different (4.8% vs 5.3%; RR 0.92, p = 0.092)."

Checkpoint inhibition • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Oncology • Septic Shock • Solid Tumor

Clinical Characteristics and Treatment Outcomes of Immune Checkpoint Inhibitor-Associated Colitis (ACG 2026) - "ICIs used were pembrolizumab (n=18), durvalumab (n=13), nivolumab (n=12), ipilimumab (n=4), atezolizumab (n=5), bevacizumab (n=3), tremelimumab (n=3), cabozantinib (n=2), and lenvatinib (n=1)... Clinical severity and endoscopic findings were associated with the need for drug therapy. PL-L1 inhibitors tend to be associated with more severe disease requiring infliximab."

Checkpoint inhibition • Clinical • Breast Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology

Concurrent Immune-Related Hepatitis and Pancreatitis in a Patient Receiving Atezolizumab for Hepatocellular Carcinoma (ACG 2026) - "Case Description/ A 78-year-old female with a past medical history of metastatic breast cancer, chronic hepatitis C on Epclusa, HCC on atezolizumab/bevacizumab, initially presented with altered mental status...Following goals-of-care discussions, the patient elected for inpatient hospice and was discharged on prednisone 40 mg daily with a planned 4-week taper...Prompt recognition, discontinuation of the drug, and starting corticosteroid therapy are essential for management. Figure: Trends In Liver and Pancreatic Chemistries throughout Hospitalization"

Clinical • Breast Cancer • Cognitive Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Pancreatitis • Solid Tumor

Isolated Small Bowel Inflammation From Immune Checkpoint Inhibitor Therapy: A Case of Duodenitis and Ileitis With Colonic Sparing (ACG 2026) - "[2,3] Case Description/ A 69-year-old gentleman with Stage IIIB adenocarcinoma of colon status post right hemicolectomy was being managed on adjuvant chemotherapy with FOLFOX + Atezolizumab...AGA recommends a flexible sigmoidoscopy when suspicious for ICI-Colitis, and this case broadens the recognized spectrum of ICI gastrointestinal toxicity and emphasizes the significance of a thorough endoscopic evaluation, including upper endoscopy, when flexible sigmoidoscopy is negative. [1] Figure: Figure 1 Figure: Figures 1 & 2: The terminal ileum shows small intestinal mucosa with focal moderate acute surface inflammation with associated erosion, focal minimal acute cryptitis, focal acute cryptitis, and expansion of lamina propria by plasma cells and mixture of mononuclear inflammatory cells, including eosinophils, lymphocytes and histiocytes."

Checkpoint inhibition • Clinical • Colon Adenocarcinoma • Colon Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Peptic Ulcer • Solid Tumor

Aggressive Hepatocellular Carcinoma in a Young West African Man With Chronic Active Hepatitis B and Advanced (F3) Fibrosis Without Cirrhosis (ACG 2026) - "He was treated with atezolizumab and bevacizumab, complicated by hemoperitoneum requiring left hepatic artery embolization, with subsequent imaging showing progressive intrahepatic disease. Axial T1-weighted contrast-enhanced sequence reveals multifocal, heterogeneous lesions throughout the remaining hypertrophied left liver tissue. Calipers highlight a distinct, 17 x 12 mm subcapsular lesion along the left hepatic lobe periphery."

Metastases • Autoimmune Hepatitis • Back Pain • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cancer • Musculoskeletal Pain • Oncology • Solid Tumor • Thrombosis • AFP

Esophageal Adenocarcinoma With Neuroendocrine Differentiation: A Novel Entity Beyond the WHO Classification (ACG 2026) - "The patient received atezolizumab/carboplatin/etoposide for 4 cycles, complicated by ICI nephritis, followed by 2 cycles of carboplatin/etoposide...PET also showed progression at the GE junction, a new paraesophageal node, and a new hepatic lesion, prompting transition to irinotecan/capecitabine, then FOLFIRI, which is ongoing...Comparisons of mutation profiles with those of typical neuroendocrine carcinoma (NEC) and esophageal adenocarcinoma (EAC) are based on the published literature and may not reflect all histologic subtypes. Abbreviations: ICI = immune checkpoint inhibitor; TMB = tumor mutational burden; HRD = homologous recombination deficiency; MS = microsatellite; NEC = neuroendocrine carcinoma; EAC = esophageal adenocarcinoma; TKI = tyrosine kinase inhibitor; GSI = gamma-secretase inhibitor; PARP = poly ADP-ribose polymerase; CDK = cyclin-dependent kinase; FOLFIRI = Irinotecan/Leucovorin/Fluorouracil"

IO biomarker • Tumor mutational burden • Endocrine Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastrointestinal Disorder • Hepatology • Nephrology • Neuroendocrine Carcinoma • Neuroendocrine Neoplasm • Neuroendocrine Tumor • Oncology • Solid Tumor • HRD • SYP • TMB